#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Antisynthetase syndrome Adult T-cell lymphoma/leukaemia refractory Henoch-Schonlein purpura Oesophageal squamous cell carcinoma stage II Myeloid leukaemia Paraganglion neoplasm Hereditary ataxia Henoch-Schonlein purpura nephritis Osteopetrosis Malignant glioma Peripheral T-cell lymphoma unspecified Synovial sarcoma recurrent Anal fistula Cholangiosarcoma Synovial sarcoma More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy – Diagnostics Pulmonary fibrosis – Diagnostics Breast angiosarcoma metastatic Focal segmental glomerulosclerosis – Life with Disease Alternating hemiplegia of childhood Friedreich’s ataxia Small intestine leiomyosarcoma – Basic Information Primary biliary cholangitis – Life with Disease Waldenstrom’s macroglobulinaemia Mantle cell lymphoma stage IV – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lovastatin Zanamivir Darovasertib Ipilimumab Letetresgene Autoleucel Elenestinib Phosphate Bjt-778 D,L-Lysine Acetylsalicylate Trastuzumab Lu Ag09222 Hydralazine Hydrochloride Mitoxantrone Hydrochloride Camizestrant Cefepime Buserelin Acetate Anhydrous Caffeine Febuxostat Hemihydrate MAPLIRPACEPT GEN1078 LUNSEKIMIG More therapies…

    Learn about Your Condition

    Ocular lymphoma Myxoid liposarcoma Cystic fibrosis Hereditary angioedema Antithrombin III deficiency Frostbite Radius fracture Gallbladder cancer Spinal pain Endometrial cancer recurrent Tooth loss Carotid arteriosclerosis Endometrial cancer Bronchiectasis Multifocal motor neuropathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Glycogen storage disease type II

  • Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glycogen storage disease type II
    Germany The Netherlands

  • A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Glycogen storage disease type II
    Belgium Denmark France Germany Italy The Netherlands +1

  • Study on the Safety and Effects of SPK-3006 for Adults with Late-Onset Pompe Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glycogen storage disease type II
    Investigated Drugs:
    • Vanglusagene Ensiparvovec
    Germany

  • Study on Reducing Treatment Frequency of Alglucosidase Alfa for Elderly Patients with Late-Onset Pompe Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Glycogen storage disease type II
    Investigated Drugs:
    • Alglucosidase Alfa
    • Avalglucosidase Alfa
    • Cipaglucosidase Alfa
    The Netherlands

  • Study on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Glycogen storage disease type II
    Investigated Drugs:
    • Cipaglucosidase Alfa
    • Miglustat
    Denmark France Germany Italy The Netherlands

  • Study on the Effects of Avalglucosidase Alfa Enzyme Replacement Therapy in Patients with Pompe Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Glycogen storage disease type II
    Investigated Drugs:
    • Avalglucosidase Alfa
    Denmark
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!